Suppression of Death Receptor-mediated Apoptosis by 1,25-dihydroxyvitamin D3 Revealed by Microarray Analysis

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2005 Aug 12

PMID 16093247

Citations 28

Authors

Xiaohui Zhang

Pengfei Li

Junying Bao

Santo V Nicosia

Honggang Wang

Steven A Enkemann

Wenlong Bai

Affiliations

Soon will be listed here.

Abstract

Recent studies suggest that growth inhibition by 1,25-dihydroxyvitamin D3 represents an innovative approach to ovarian cancer therapy. To understand the molecular mechanism of 1,25-dihydroxyvitamin D3 action, we profiled the hormone-induced changes in the transcriptome of ovarian cancer cells using microarray technology. More than 200 genes were identified to be regulated by 1,25-dihydroxyvitamin D3. Reverse transcription-PCR analyses confirmed the regulation of a group of apoptosis-related genes, including the up-regulation of the decoy receptor that inhibits tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) action, TRAIL receptor 4, and the down-regulation of Fas, the receptor that mediates the action of Fas ligand. The regulation was further confirmed at the protein level. Consistent with the regulation of the death receptors, pretreatment with 1,25-dihydroxyvitamin D3 decreased apoptosis induced by TRAIL and Fas ligand. Because persistent 1,25-dihydroxyvitamin D3 treatment has been shown to induce apoptosis in ovarian cancer, the hormone appears to exert a dual effect on the death of ovarian cancer cells. Knockdown of TRAIL receptor 4 by RNA interference or ectopic expression of Fas relieved the suppressive effect of 1,25-dihydroxyvitamin D3, showing that molecular manipulation of death receptors is a viable approach to overcome the protective effect of 1,25-dihydroxyvitamin D3 on the apoptosis of ovarian cancer. These strategies may allow ovarian cancer patients to benefit from therapy with both 1,25-dihydroxyvitamin D3 and ligands for death receptors, such as TRAIL, shown to selectively induce apoptosis in cancer but not normal cells.

Citing Articles

Biochemical mechanisms and molecular interactions of vitamins in cancer therapy.

Aborode A, Onifade I, Olorunshola M, Adenikinju G, Aruorivwooghene I, Femi A Cancer Pathog Ther. 2025; 3(1):3-15.

PMID: 39872372 PMC: 11764782. DOI: 10.1016/j.cpt.2024.05.001.

Serum 25-hydroxyvitamin D concentrations and their impact on all-cause mortality in Parkinson's disease: insights from National Health and Nutrition Examination Survey 1999-2020 data.

Yong Y, Dong H, Zhou Z, Zhu Y, Gu M, Li W Front Nutr. 2024; 11:1423651.

PMID: 39183989 PMC: 11341485. DOI: 10.3389/fnut.2024.1423651.

Cholecalciferol (VD3) Attenuates L-DOPA-Induced Dyskinesia in Parkinsonian Mice Via Modulation of Microglia and Oxido-Inflammatory Mechanisms.

Bayo-Olugbami A, Nafiu A, Amin A, Ogundele O, Lee C, Owoyele B Niger J Physiol Sci. 2024; 37(2):175-183.

PMID: 38243560 PMC: 10800002. DOI: 10.54548/njps.v37i2.3.

A Newly Identified lncBCAS1-4_1 Associated With Vitamin D Signaling and EMT in Ovarian Cancer Cells.

Xue Y, Wang P, Jiang F, Yu J, Ding H, Zhang Z Front Oncol. 2021; 11:691500.

PMID: 34422647 PMC: 8377733. DOI: 10.3389/fonc.2021.691500.

Is Vitamin D Deficiency Related to Increased Cancer Risk in Patients with Type 2 Diabetes Mellitus?.

Gabryanczyk A, Klimczak S, Szymczak-Pajor I, Sliwinska A Int J Mol Sci. 2021; 22(12).

PMID: 34208589 PMC: 8233804. DOI: 10.3390/ijms22126444.

References

Tusher V, Tibshirani R, Chu G . Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001; 98(9):5116-21. PMC: 33173. DOI: 10.1073/pnas.091062498. View

Cmarik J, Min H, Hegamyer G, Zhan S, Kulesz-Martin M, Yoshinaga H . Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci U S A. 1999; 96(24):14037-42. PMC: 24186. DOI: 10.1073/pnas.96.24.14037. View

Maurer U, Jehan F, Englert C, Hubinger G, Weidmann E, DeLuca H . The Wilms' tumor gene product (WT1) modulates the response to 1,25-dihydroxyvitamin D3 by induction of the vitamin D receptor. J Biol Chem. 2000; 276(6):3727-32. DOI: 10.1074/jbc.M005292200. View

Akutsu N, Lin R, Bastien Y, Bestawros A, Enepekides D, Black M . Regulation of gene Expression by 1alpha,25-dihydroxyvitamin D3 and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma Cells. Mol Endocrinol. 2001; 15(7):1127-39. DOI: 10.1210/mend.15.7.0655. View

Shen Z, Wu M, Elson P, Kennedy A, Belinson J, Casey G . Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases. Gynecol Oncol. 2001; 83(1):25-30. DOI: 10.1006/gyno.2001.6357. View

Belcredito S, Vegeto E, Brusadelli A, Ghisletti S, Mussi P, Ciana P . Estrogen neuroprotection: the involvement of the Bcl-2 binding protein BNIP2. Brain Res Brain Res Rev. 2001; 37(1-3):335-42. DOI: 10.1016/s0165-0173(01)00138-2. View

Cippitelli M, Fionda C, Di Bona D, Di Rosa F, Lupo A, Piccoli M . Negative regulation of CD95 ligand gene expression by vitamin D3 in T lymphocytes. J Immunol. 2002; 168(3):1154-66. DOI: 10.4049/jimmunol.168.3.1154. View

Lin R, Nagai Y, Sladek R, Bastien Y, Ho J, Petrecca K . Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol. 2002; 16(6):1243-56. DOI: 10.1210/mend.16.6.0874. View

Gurlek A, Pittelkow M, Kumar R . Modulation of growth factor/cytokine synthesis and signaling by 1alpha,25-dihydroxyvitamin D(3): implications in cell growth and differentiation. Endocr Rev. 2002; 23(6):763-86. DOI: 10.1210/er.2001-0044. View

10.

Guzey M, Kitada S, Reed J . Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther. 2002; 1(9):667-77. View

11.

Miettinen S, Ahonen M, Lou Y, Manninen T, Tuohimaa P, Syvala H . Role of 24-hydroxylase in vitamin D3 growth response of OVCAR-3 ovarian cancer cells. Int J Cancer. 2003; 108(3):367-73. DOI: 10.1002/ijc.11520. View

12.

Diker-Cohen T, Koren R, Liberman U, Ravid A . Vitamin D protects keratinocytes from apoptosis induced by osmotic shock, oxidative stress, and tumor necrosis factor. Ann N Y Acad Sci. 2004; 1010:350-3. DOI: 10.1196/annals.1299.064. View

13.

Weitsman G, Ravid A, Liberman U, Koren R . Vitamin D enhances caspase-dependent and independent TNF-induced breast cancer cell death: the role of reactive oxygen species. Ann N Y Acad Sci. 2004; 1010:437-40. DOI: 10.1196/annals.1299.079. View

14.

Krishnan A, Shinghal R, Raghavachari N, Brooks J, Peehl D, Feldman D . Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate. 2004; 59(3):243-51. DOI: 10.1002/pros.20006. View

15.

Stewart L, Weigel N . Vitamin D and prostate cancer. Exp Biol Med (Maywood). 2004; 229(4):277-84. DOI: 10.1177/153537020422900401. View

16.

Behrens P, Brinkmann U, Wellmann A . CSE1L/CAS: its role in proliferation and apoptosis. Apoptosis. 2003; 8(1):39-44. DOI: 10.1023/a:1021644918117. View

17.

Johansen C, Kragballe K, Henningsen J, Westergaard M, Kristiansen K, Iversen L . 1alpha,25-dihydroxyvitamin D3 stimulates activator protein 1 DNA-binding activity by a phosphatidylinositol 3-kinase/Ras/MEK/extracellular signal regulated kinase 1/2 and c-Jun N-terminal kinase 1-dependent increase in c-Fos, Fra1, and c-Jun.... J Invest Dermatol. 2003; 120(4):561-70. DOI: 10.1046/j.1523-1747.2003.12095.x. View

18.

Barila D, Rufini A, Condo I, Ventura N, Dorey K, Superti-Furga G . Caspase-dependent cleavage of c-Abl contributes to apoptosis. Mol Cell Biol. 2003; 23(8):2790-9. PMC: 152541. DOI: 10.1128/MCB.23.8.2790-2799.2003. View

19.

De Haes P, Garmyn M, Degreef H, Vantieghem K, Bouillon R, Segaert S . 1,25-Dihydroxyvitamin D3 inhibits ultraviolet B-induced apoptosis, Jun kinase activation, and interleukin-6 production in primary human keratinocytes. J Cell Biochem. 2003; 89(4):663-73. DOI: 10.1002/jcb.10540. View

20.

Swami S, Raghavachari N, Muller U, Bao Y, Feldman D . Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. Breast Cancer Res Treat. 2003; 80(1):49-62. DOI: 10.1023/A:1024487118457. View